| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.32 | 5e-08 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.22 | 1e-07 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-07 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.24 | 1e-07 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.29 | 8e-07 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.3 | 9e-07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.2 | 2e-06 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-06 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-06 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-06 |